EGFR and non-small cell lung carcinoma: Currently, the prospective clinical trial GASTO1002 that we initiated is ongoing to explore 6-month or 12-month icotinib following chemotherapy to see how well it works compared to chemotherapy alone in treating patients with resected stage IIA-IIIA NSCLC harboring EGFR mutation (NCT01996098).